Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Glycostem tech schreef op 2 augustus 2015 18:22 :
As midsize investor we are careful with GLPG and sold a large position end of last week. We all know the Pfizer story regarding Xeljanz (tofacitinib) - which is comparable to filgotinib as a JAK- inhibitor. Although, now approved by the FDA for the US market - European approval was turned down due to overall safety concerns and serious side effects. So far, in Darwin studies there are less than 600 patients only (including low dose and placebo groups) and already one death in the verum group due to pneumonia ! Approval for tofacitinib was denied in the EU after records of 3300 patient files were submitted - and benefits of this drug did not outweigh the risks (immunosuppression, liver damage, cancer and gastro-intestinal perforations). Pfizer shares dropped 3% after the announcement of 4 tofacitinib related death in 2011. Galapagos market value heavily depends (at least at the moment) on this single drug - all others are still too far from market.
One should think about it.
The cause of death was not relatable to filgotinib.. people die every day. Can you show us the phase two 24 week results of tofacitinib ? It doesnt make sense saying something is comparable and not actually show the comparisons..
Glycostem tech schreef op 2 augustus 2015 18:22 :
As midsize investor we are careful with GLPG and sold a large position end of last week. We all know the Pfizer story regarding Xeljanz (tofacitinib) - which is comparable to filgotinib as a JAK- inhibitor. Although, now approved by the FDA for the US market - European approval was turned down due to overall safety concerns and serious side effects. So far, in Darwin studies there are less than 600 patients only (including low dose and placebo groups) and already one death in the verum group due to pneumonia ! Approval for tofacitinib was denied in the EU after records of 3300 patient files were submitted - and benefits of this drug did not outweigh the risks (immunosuppression, liver damage, cancer and gastro-intestinal perforations). Pfizer shares dropped 3% after the announcement of 4 tofacitinib related death in 2011. Galapagos market value heavily depends (at least at the moment) on this single drug - all others are still too far from market.
One should think about it.
Midsize investor who publish this in a forum, very funny :-)) So you sold and now you are so noble to warn other investors, also very funny :-))) For a midsize investor you are pretty badly informed... Maybe you should go back to the playground and return to play with the other kids..
Ik wist al niet zo goed waarom de koers op nasdaq de hoogte in ging en ook niet vanwaar de aandelen kwamen. Nu (betaald?) hier wat komen bashen en de koers naar beneden praten om opnieuw wat in te slaan en dan weer aandelen op nasdaq te kunnen verkopen, geleend of getransfereerd, what ever. Nou dat hebben we net nodig om angsthazen het veld in te jagen. Profiteer van de mogelijke dips zou ik zo zeggen. Succes gegarandeerd :-( PS. kan jij Nederlands praten? Je zou meer succes kunnen hebben imo. Het valt namelijk minder op...
Glycostem tech DETAILS Lid sinds 31 jul 2015 Laatste bezoek 02 aug 2015 Aantal posts 2 Gegeven aanbevelingen 0 Ontvangen aanbevelingen 0 Aanbevelingen/Posts 0,0000
djyves schreef op 2 augustus 2015 12:06 :
Verwachtingen voor Maandag 10 Augustus slotkoers (in Euro):
Grapesharvester 70
Springinhetveld 65,49
MtBaker 63.47
Wonderwoman 62,22
SJURMV 61,00
Gorden Gekko 60,05
Hee jij ook hier 58.25
Mooiweer 57.50
Alan B'stard 52-56+
Ruud Rubbers 59,00
mickjagger2 € 61,25
biffy € 56,43
djvyes € 55,00
Nagenoeg al deze mensen gaan morgen bestens bijkopen bij opening? Is toch een mooi rendement in ruim een week....
mr. gala schreef op 2 augustus 2015 20:58 :
[...]
Nagenoeg al deze mensen gaan morgen bestens bijkopen bij opening? Is toch een mooi rendement in ruim een week....
Heb al genoeg gekocht en ben niet zo hebberig, je moet tenslotte een ander ook wat gunnen, toch?
56.30 ik kan niet meer bijkopen. Heb geen cash niet meer
Ik kijk morgen wel hoeveel bestens orders er zijn,en hoeveel aandelen dat worden.Als er niemand wil verkopen word het dus een freeze.
Verwachtingen voor Maandag 10 Augustus slotkoers (in Euro): Grapesharvester 70 Springinhetveld 65,49 MtBaker 63.47 Wonderwoman 62,22 SJURMV 61,00 Gorden Gekko 60,05 Hee jij ook hier 58.25 Mooiweer 57.50 Alan B'stard 52-56+ Ruud Rubbers 59,00 mickjagger2 € 61,25 biffy € 56,43 djvyes € 55,00 Bogo € 58,85
Ik gun grapesharvester de overwinning, en dat terwijl ie er eur 20 naast zit ;)
Verwachtingen voor Maandag 10 Augustus slotkoers (in Euro): Grapesharvester 70 Springinhetveld 65,49 MtBaker 63.47 Wonderwoman 62,22 mickjagger2 € 61,25 SJURMV 61,00 Gorden Gekko 60,05 Ruud rubbers 59 Bogo 58,55 Hee jij ook hier 58.25 Mooiweer 57.50 Biffy 56.43 Grrrrr PFFFFF zucht 56.2 Twinkletown 54,50 en 55,50 Djyves 53 en 55 Alan B'stard 52-56+
MtBaker schreef op 2 augustus 2015 22:20 :
Verwachtingen voor Maandag 10 Augustus slotkoers (in Euro):
Grapesharvester 70
Springinhetveld 65,49
MtBaker 63.47
Wonderwoman 62,22
mickjagger2 € 61,25
SJURMV 61,00
Gorden Gekko 60,05
Ruud rubbers 59
Bogo 58,55
Hee jij ook hier 58.25
Mooiweer 57.50
Biffy 56.43
Grrrrr PFFFFF zucht 56.2
Twinkletown 54,50 en 55,50
Cees01 53.85
Djyves 53 en 55
Alan B'stard 52-56+
MtBaker schreef op 2 augustus 2015 22:20 :
Verwachtingen voor Maandag 10 Augustus slotkoers (in Euro):
Grapesharvester 70
Springinhetveld 65,49
MtBaker 63.47
Wonderwoman 62,22
mickjagger2 € 61,25
SJURMV 61,00
Gorden Gekko 60,05
Ruud rubbers 59
Bogo 58,55
Hee jij ook hier 58.25
Mooiweer 57.50
Biffy 56.43
Grrrrr PFFFFF zucht 56.2
Twinkletown 54,50 en 55,50
Djyves 53 en 55
Alan B'stard 52-56+
Hey mr. Baker ik zie dat je mijn verwachting voor 10 augustus van € 58,85 veranderd heb in € 58,55 waarschijnlijk heb je alles handmatig veranderd en is daar de fout ontstaan, geeft niks hoor, ik vind het leuk dat je mij wil laten winnen maar dat doe ik liever op een eerlijke manier. Even goede vrienden en mijn voorspelling is dus € 58,85 groet Bogo.
Glycostem tech schreef op 2 augustus 2015 18:22 :
As midsize investor we are careful with GLPG and sold a large position end of last week. We all know the Pfizer story regarding Xeljanz (tofacitinib) - which is comparable to filgotinib as a JAK- inhibitor. Although, now approved by the FDA for the US market - European approval was turned down due to overall safety concerns and serious side effects. So far, in Darwin studies there are less than 600 patients only (including low dose and placebo groups) and already one death in the verum group due to pneumonia ! Approval for tofacitinib was denied in the EU after records of 3300 patient files were submitted - and benefits of this drug did not outweigh the risks (immunosuppression, liver damage, cancer and gastro-intestinal perforations). Pfizer shares dropped 3% after the announcement of 4 tofacitinib related death in 2011. Galapagos market value heavily depends (at least at the moment) on this single drug - all others are still too far from market.
One should think about it.
As far as we know to this date, Filgotinib does not have any of the risks that you associated with tofacitinib such as "immunosuppression, liver damage, cancer and gastro-intestinal perforations." Therefore, your comment is actually misleading. You should not compare Filgotinib to Tofacitinib in the manner in which you did it. It is very unprofessional, given that you call yourself a "midsize investor." I suggest that you should do a better and more objective research on filgotinib. Galapagos has a lot of potential. If we take into account the major products in Galapagos' pipeline, I think that most fair-minded people would agree that Galapagos' current share price (60,65 dollars) is significantly under valued. If Galapagos were to be an American company, with all the fantastic results the company has produced so far, it would have been trading at somewhere between 100 to 150 dollars by now. It seems as if European pharmaceutical companies tend to get lower valuations than their American counterparts and this is not fair. This practise must be corrected!
Investor68 schreef op 3 augustus 2015 00:25 :
[...vAs far as we know to this date, Filgotinib
does not have any of the risks that you associated with tofacitinib such as "immunosuppression, liver damage, cancer and gastro-intestinal perforations." Therefore, your comment is actually misleading. You should not compare Filgotinib to Tofacitinib in the manner in which you did it. It is very unprofessional, given that you call yourself a "midsize investor." I suggest that you should do a better and more objective research on filgotinib. Galapagos has a lot of potential. If we take into account the major products in Galapagos' pipeline, I think that most fair-minded people would agree that Galapagos' current share price (60,65 dollars) is significantly
under valued. If Galapagos were to be an American company, with all the fantastic results the company has produced so far, it would have been trading at somewhere between 100 to 150 dollars by now. It seems as if European pharmaceutical companies tend to get lower valuations than their American counterparts and this is not fair. This practise must be corrected!
I just think this man/woman is really funny, by posting this bullshit.. Most of all I find it funny that this child thinks he/she can make this share go down... Get a life and find a regular job, because investing is not gonna bring you any money... Just buy a few Galapagos shares and you might earn a few euro's...(,maybe you van buy a share or two) Nobody is gonna believe your bullshit...
Nog meer problemen met inloggen bij binck?
Ik ook, pin werkt niet meer!
Eerst anderhalve dag onderhoud plegen met dit als resultaat, kneuzen.
mr. gala schreef op 3 augustus 2015 09:14 :
Nog meer problemen met inloggen bij binck?
Jaja, je bent niet alleen met dat probleem
55 is doorbroken, dat maakt een hoop goed ;)
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)